Stem cell therapeutics firm Aldagen acquired by Cytomedix in stock deal
Regenerative medicine company Cytomedix (OTC:CMXI) has acquired North Carolina stem cell technology company Aldagen in a stock deal valued at $40 million that broadens the firm’s regenerative therapies pipeline. Maryland-based Cytomedix develops biologically active regenerative therapies for wound care, inflammation and blood vessel development. The company has been diversifying to build its …
[Read the full article here]Related News:
Cytomedix Picks Up Stem Cell Therapy Firm Aldagen
Cytomedix snaps up stem cell biotech Aldagen for a bargain price
Stem cell therapeutics firm Aldagen expands fundraiser to $645K